442 related articles for article (PubMed ID: 32400885)
21. Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions.
Fischer K; Al-Sawaf O; Bahlo J; Fink AM; Tandon M; Dixon M; Robrecht S; Warburton S; Humphrey K; Samoylova O; Liberati AM; Pinilla-Ibarz J; Opat S; Sivcheva L; Le Dû K; Fogliatto LM; Niemann CU; Weinkove R; Robinson S; Kipps TJ; Boettcher S; Tausch E; Humerickhouse R; Eichhorst B; Wendtner CM; Langerak AW; Kreuzer KA; Ritgen M; Goede V; Stilgenbauer S; Mobasher M; Hallek M
N Engl J Med; 2019 Jun; 380(23):2225-2236. PubMed ID: 31166681
[TBL] [Abstract][Full Text] [Related]
22. Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study.
Stilgenbauer S; Bosch F; Ilhan O; Kisro J; Mahé B; Mikuskova E; Osmanov D; Reda G; Robinson S; Tausch E; Turgut M; Wójtowicz M; Böttcher S; Perretti T; Trask P; Van Hoef M; Leblond V; Foà R
Br J Haematol; 2021 Apr; 193(2):325-338. PubMed ID: 33605445
[TBL] [Abstract][Full Text] [Related]
23. First-line therapy in chronic lymphocytic leukemia: a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013.
Sylvan SE; Asklid A; Johansson H; Klintman J; Bjellvi J; Tolvgård S; Kimby E; Norin S; Andersson PO; Karlsson C; Karlsson K; Lauri B; Mattsson M; Sandstedt AB; Strandberg M; Österborg A; Hansson L
Haematologica; 2019 Apr; 104(4):797-804. PubMed ID: 30467205
[TBL] [Abstract][Full Text] [Related]
24. Obinutuzumab treatment in the elderly patient with chronic lymphocytic leukemia.
Seiter K; Mamorska-Dyga A
Clin Interv Aging; 2015; 10():951-61. PubMed ID: 26109852
[TBL] [Abstract][Full Text] [Related]
25. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial.
Moreno C; Greil R; Demirkan F; Tedeschi A; Anz B; Larratt L; Simkovic M; Samoilova O; Novak J; Ben-Yehuda D; Strugov V; Gill D; Gribben JG; Hsu E; Lih CJ; Zhou C; Clow F; James DF; Styles L; Flinn IW
Lancet Oncol; 2019 Jan; 20(1):43-56. PubMed ID: 30522969
[TBL] [Abstract][Full Text] [Related]
26. Bendamustin-Rituximab Combination Is a Safe and Effective, Ambulatory Treatment for Elderly Patients with Chronic Lymphocytic Leukemia: Retrospective Real-world Analysis by Age from a German Registry and Review of the Literature.
Kleeberg UR; Linde H; Günther G; Tessen HW; Kersting M
Anticancer Res; 2016 Jun; 36(6):2827-38. PubMed ID: 27272794
[TBL] [Abstract][Full Text] [Related]
27. Obinutuzumab Plus Chlorambucil in a Patient with Severe Myasthenia Gravis and Chronic Lymphocytic Leukemia.
Russell A; Yaraskavitch M; Fok D; Chhibber S; Street L; Korngut L
J Neuromuscul Dis; 2017; 4(3):251-257. PubMed ID: 28869483
[TBL] [Abstract][Full Text] [Related]
28. Outcome of patients aged 80 years or older treated for chronic lymphocytic leukaemia.
Al-Sawaf O; Bahlo J; Robrecht S; Fischer K; Herling CD; Hoechstetter M; Fink AM; von Tresckow J; Langerbeins P; Cramer P; Stilgenbauer S; Wendtner CM; Eichhorst B; Hallek M; Goede V
Br J Haematol; 2018 Dec; 183(5):727-735. PubMed ID: 30460980
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United States.
Chatterjee A; Shapouri S; Manzoor BS; Ravelo A; Sail K; Qendri V; van de Wetering G; Davids MS
J Manag Care Spec Pharm; 2021 Nov; 27(11):1532-1544. PubMed ID: 34714110
[No Abstract] [Full Text] [Related]
30. Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapy.
Herling CD; Klaumünzer M; Rocha CK; Altmüller J; Thiele H; Bahlo J; Kluth S; Crispatzu G; Herling M; Schiller J; Engelke A; Tausch E; Döhner H; Fischer K; Goede V; Nürnberg P; Reinhardt HC; Stilgenbauer S; Hallek M; Kreuzer KA
Blood; 2016 Jul; 128(3):395-404. PubMed ID: 27226433
[TBL] [Abstract][Full Text] [Related]
31. [Efficacy of a bendamustine and rituximab combination in first-line therapy for chronic lymphocytic leukemia: Results of the BEN-001 study].
Stadnik EA; Strugov VV; Andreeva TO; Virts YV; Rumyantsev AM; Mirolyubova YV; Butylin PA; Zaritsky AY
Ter Arkh; 2017; 89(7):57-64. PubMed ID: 28766542
[TBL] [Abstract][Full Text] [Related]
32. Obinutuzumab plus fludarabine/cyclophosphamide or bendamustine in the initial therapy of CLL patients: the phase 1b GALTON trial.
Brown JR; O'Brien S; Kingsley CD; Eradat H; Pagel JM; Lymp J; Hirata J; Kipps TJ
Blood; 2015 Apr; 125(18):2779-85. PubMed ID: 25769620
[TBL] [Abstract][Full Text] [Related]
33. A network meta-analysis of progression free survival and overall survival in first-line treatment of chronic lymphocytic leukemia.
Ladyzynski P; Molik M; Foltynski P
Cancer Treat Rev; 2015 Feb; 41(2):77-93. PubMed ID: 25512118
[TBL] [Abstract][Full Text] [Related]
34. Obinutuzumab: a review of its use in patients with chronic lymphocytic leukaemia.
Hoy SM
Drugs; 2015 Feb; 75(3):285-96. PubMed ID: 25586272
[TBL] [Abstract][Full Text] [Related]
35. Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the phase IIIb GREEN study.
Leblond V; Aktan M; Ferra Coll CM; Dartigeas C; Kisro J; Montillo M; Raposo J; Merot JL; Robson S; Gresko E; Bosch F; Stilgenbauer S; Foà R
Haematologica; 2018 Nov; 103(11):1889-1898. PubMed ID: 29976743
[TBL] [Abstract][Full Text] [Related]
36. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients.
Foà R; Del Giudice I; Cuneo A; Del Poeta G; Ciolli S; Di Raimondo F; Lauria F; Cencini E; Rigolin GM; Cortelezzi A; Nobile F; Callea V; Brugiatelli M; Massaia M; Molica S; Trentin L; Rizzi R; Specchia G; Di Serio F; Orsucci L; Ambrosetti A; Montillo M; Zinzani PL; Ferrara F; Morabito F; Mura MA; Soriani S; Peragine N; Tavolaro S; Bonina S; Marinelli M; De Propris MS; Starza ID; Piciocchi A; Alietti A; Runggaldier EJ; Gamba E; Mauro FR; Chiaretti S; Guarini A
Am J Hematol; 2014 May; 89(5):480-6. PubMed ID: 24415640
[TBL] [Abstract][Full Text] [Related]
37. Treating chronic lymphocytic leukemia with obinutuzumab: safety and efficacy considerations.
Reda G; Orofino N; Cassin R; Sciumè M; Fattizzo B; Cortelezzi A
Expert Opin Drug Saf; 2016 Jun; 15(6):865-73. PubMed ID: 26967902
[TBL] [Abstract][Full Text] [Related]
38. Obinutuzumab for chronic lymphocytic leukemia: promise of the first treatment approved with breakthrough therapy designation.
Kakkar AK; Balakrishnan S
J Oncol Pharm Pract; 2015 Oct; 21(5):358-63. PubMed ID: 24827578
[TBL] [Abstract][Full Text] [Related]
39. Venetoclax plus bendamustine-rituximab or bendamustine-obinutuzumab in chronic lymphocytic leukemia: final results of a phase 1b study (GO28440).
Stilgenbauer S; Morschhauser F; Wendtner CM; Cartron G; Hallek M; Eichhorst B; Kozloff MF; Giever T; Lozanski G; Jiang Y; Huang H; Pignataro DS; Schary W; Humphrey K; Mobasher M; Salles G
Haematologica; 2021 Nov; 106(11):2834-2844. PubMed ID: 33121235
[TBL] [Abstract][Full Text] [Related]
40. Akt inhibitor MK-2206 in combination with bendamustine and rituximab in relapsed or refractory chronic lymphocytic leukemia: Results from the N1087 alliance study.
Larsen JT; Shanafelt TD; Leis JF; LaPlant B; Call T; Pettinger A; Hanson C; Erlichman C; Habermann TM; Reeder C; Nikcevich D; Bowen D; Conte M; Boysen J; Secreto C; Lesnick C; Tschumper R; Jelinek D; Kay NE; Ding W
Am J Hematol; 2017 Aug; 92(8):759-763. PubMed ID: 28402581
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
